Courts Raise Evidentiary Standards for Expert Witnesses in Drug Patent Litigation

Recent legal decisions have marked a shift in the landscape of drug patent litigation, specifically within the context of Hatch-Waxman cases. Courts are increasingly demanding rigorous methodologies from expert witnesses involved in pharmaceutical patent disputes. This trend compels legal practitioners to meticulously strategize their use of expert testimony, ensuring alignment with venue-specific expectations. As the dynamic between brand and generic-drug manufacturers continues to evolve, litigators must navigate these challenges with a nuanced understanding of the heightened evidentiary standards now influencing case outcomes. Jeremy Scholem at WIT Legal highlights the critical nature of this development for professionals engaged in this specialized area of law.